ID   HUWE1_HUMAN             Reviewed;        4374 AA.
AC   Q7Z6Z7; O15029; Q4G2Z2; Q5H961; Q6P4D0; Q8NG67; Q9BUI0; Q9HCJ4;
AC   Q9NSL6; Q9P0A9;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   30-AUG-2005, sequence version 3.
DT   10-MAY-2017, entry version 157.
DE   RecName: Full=E3 ubiquitin-protein ligase HUWE1;
DE            EC=2.3.2.26;
DE   AltName: Full=ARF-binding protein 1;
DE            Short=ARF-BP1;
DE   AltName: Full=HECT, UBA and WWE domain-containing protein 1;
DE   AltName: Full=HECT-type E3 ubiquitin transferase HUWE1;
DE   AltName: Full=Homologous to E6AP carboxyl terminus homologous protein 9;
DE            Short=HectH9;
DE   AltName: Full=Large structure of UREB1;
DE            Short=LASU1;
DE   AltName: Full=Mcl-1 ubiquitin ligase E3;
DE            Short=Mule;
DE   AltName: Full=Upstream regulatory element-binding protein 1;
DE            Short=URE-B1;
DE            Short=URE-binding protein 1;
GN   Name=HUWE1; Synonyms=KIAA0312, KIAA1578, UREB1; ORFNames=HSPC272;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, INTERACTION WITH
RP   CDKN2A, AND MUTAGENESIS OF CYS-4341.
RX   PubMed=15989956; DOI=10.1016/j.cell.2005.03.037;
RA   Chen D., Kon N., Li M., Zhang W., Qin J., Gu W.;
RT   "ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.";
RL   Cell 121:1071-1083(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND MUTAGENESIS OF
RP   CYS-4341.
RX   PubMed=15989957; DOI=10.1016/j.cell.2005.06.009;
RA   Zhong Q., Gao W., Du F., Wang X.;
RT   "Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the
RT   polyubiquitination of Mcl-1 and regulates apoptosis.";
RL   Cell 121:1085-1095(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION.
RX   PubMed=15767685; DOI=10.1128/MCB.25.7.2819-2831.2005;
RA   Liu Z., Oughtred R., Wing S.S.;
RT   "Characterization of E3Histone, a novel testis ubiquitin protein
RT   ligase which ubiquitinates histones.";
RL   Mol. Cell. Biol. 25:2819-2831(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15772651; DOI=10.1038/nature03440;
RA   Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D.,
RA   Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A.,
RA   Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G.,
RA   Jones M.C., Hurles M.E., Andrews T.D., Scott C.E., Searle S.,
RA   Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R.,
RA   Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L.,
RA   Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A.,
RA   Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S.,
RA   Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R.,
RA   Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M.,
RA   Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N.,
RA   Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D.,
RA   Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W.,
RA   Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C.,
RA   Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C.,
RA   Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S.,
RA   Corby N., Connor R.E., David R., Davies J., Davis C., Davis J.,
RA   Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S.,
RA   Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I.,
RA   Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L.,
RA   Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P.,
RA   Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S.,
RA   Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A.,
RA   Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J.,
RA   Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J.,
RA   Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S.,
RA   de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z.,
RA   Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C.,
RA   Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W.,
RA   Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D.,
RA   Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H.,
RA   McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T.,
RA   Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I.,
RA   Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N.,
RA   Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J.,
RA   Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E.,
RA   Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S.,
RA   Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K.,
RA   Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D.,
RA   Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R.,
RA   Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T.,
RA   Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S.,
RA   Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L.,
RA   Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A.,
RA   Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L.,
RA   Williams G., Williams L., Williamson A., Williamson H., Wilming L.,
RA   Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H.,
RA   Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A.,
RA   Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F.,
RA   Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A.,
RA   Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T.,
RA   Gibbs R.A., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence of the human X chromosome.";
RL   Nature 434:325-337(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 959-4374 (ISOFORM 3).
RC   TISSUE=Brain;
RA   Miyazaki K., Okamoto Y., Sakamoto M., Kato C., Ozaki T., Watanabe K.,
RA   Nakagawara A.;
RT   "Homo sapiens LASU1 (large structure of UREB1) mRNA, complete cds.";
RL   Submitted (SEP-2001) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1166-4374 (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=9205841; DOI=10.1093/dnares/4.2.141;
RA   Nagase T., Ishikawa K., Nakajima D., Ohira M., Seki N., Miyajima N.,
RA   Tanaka A., Kotani H., Nomura N., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. VII.
RT   The complete sequences of 100 new cDNA clones from brain which can
RT   code for large proteins in vitro.";
RL   DNA Res. 4:141-150(1997).
RN   [7]
RP   SEQUENCE REVISION TO 2310.
RA   Ohara O., Nagase T., Kikuno R., Nomura N.;
RL   Submitted (SEP-2011) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1246-2418.
RC   TISSUE=Brain;
RX   PubMed=10997877; DOI=10.1093/dnares/7.4.271;
RA   Nagase T., Kikuno R., Nakayama M., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes.
RT   XVIII. The complete sequences of 100 new cDNA clones from brain which
RT   code for large proteins in vitro.";
RL   DNA Res. 7:273-281(2000).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2451-4374.
RC   TISSUE=Umbilical cord blood;
RX   PubMed=11042152; DOI=10.1101/gr.140200;
RA   Zhang Q.-H., Ye M., Wu X.-Y., Ren S.-X., Zhao M., Zhao C.-J., Fu G.,
RA   Shen Y., Fan H.-Y., Lu G., Zhong M., Xu X.-R., Han Z.-G., Zhang J.-W.,
RA   Tao J., Huang Q.-H., Zhou J., Hu G.-X., Gu J., Chen S.-J., Chen Z.;
RT   "Cloning and functional analysis of cDNAs with open reading frames for
RT   300 previously undefined genes expressed in CD34+ hematopoietic
RT   stem/progenitor cells.";
RL   Genome Res. 10:1546-1560(2000).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 3953-4374.
RC   TISSUE=Ovary, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4029-4374.
RA   Kim J.W., Lee Y., Hong Y.M., Hong M., Choe I.S.;
RL   Submitted (APR-1998) to the EMBL/GenBank/DDBJ databases.
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 4067-4374.
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 4320-4374.
RC   TISSUE=Melanoma;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [14]
RP   FUNCTION, TISSUE SPECIFICITY, AND MUTAGENESIS OF TYR-4268 AND
RP   CYS-4341.
RX   PubMed=15567145; DOI=10.1016/j.bbrc.2004.11.004;
RA   Yoon S.Y., Lee Y., Kim J.H., Chung A.-S., Joo J.H., Kim C.-N.,
RA   Kim N.-S., Choe I.S., Kim J.W.;
RT   "Over-expression of human UREB1 in colorectal cancer: HECT domain of
RT   human UREB1 inhibits the activity of tumor suppressor p53 protein.";
RL   Biochem. Biophys. Res. Commun. 326:7-17(2005).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2362, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1395; SER-1907;
RP   SER-2362; SER-2887 AND SER-2918, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH CDC6.
RX   PubMed=17567951; DOI=10.1091/mbc.E07-02-0173;
RA   Hall J.R., Kow E., Nevis K.R., Lu C.K., Luce K.S., Zhong Q.,
RA   Cook J.G.;
RT   "Cdc6 stability is regulated by the Huwe1 ubiquitin ligase after DNA
RT   damage.";
RL   Mol. Biol. Cell 18:3340-3350(2007).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1084, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2362, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [22]
RP   FUNCTION, INTERACTION WITH MYCN, AND MUTAGENESIS OF CYS-4341.
RX   PubMed=18488021; DOI=10.1038/ncb1727;
RA   Zhao X., Heng J.I.-T., Guardavaccaro D., Jiang R., Pagano M.,
RA   Guillemot F., Iavarone A., Lasorella A.;
RT   "The HECT-domain ubiquitin ligase Huwe1 controls neural
RT   differentiation and proliferation by destabilizing the N-Myc
RT   oncoprotein.";
RL   Nat. Cell Biol. 10:643-653(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1368; SER-1907;
RP   SER-2362; SER-2365; SER-2887; SER-3662; SER-3919; THR-3924 AND
RP   THR-3927, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [24]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [25]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH POLB.
RX   PubMed=19713937; DOI=10.1038/emboj.2009.243;
RA   Parsons J.L., Tait P.S., Finch D., Dianova I.I., Edelmann M.J.,
RA   Khoronenkova S.V., Kessler B.M., Sharma R.A., McKenna W.G.,
RA   Dianov G.L.;
RT   "Ubiquitin ligase ARF-BP1/Mule modulates base excision repair.";
RL   EMBO J. 28:3207-3215(2009).
RN   [26]
RP   FUNCTION, AND INTERACTION WITH PA2G4.
RX   PubMed=19037095; DOI=10.1091/mbc.E08-09-0983;
RA   Liu Z., Oh S.M., Okada M., Liu X., Cheng D., Peng J., Brat D.J.,
RA   Sun S.Y., Zhou W., Gu W., Ye K.;
RT   "Human BRE1 is an E3 ubiquitin ligase for Ebp1 tumor suppressor.";
RL   Mol. Biol. Cell 20:757-768(2009).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1370; SER-1395;
RP   SER-1907; SER-2362; SER-2391; SER-2595; SER-2619; THR-2751; SER-2887;
RP   SER-3116; SER-3752; SER-3757; SER-3808; SER-3816; SER-3919 AND
RP   THR-3924, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1084; SER-1368;
RP   SER-1395; THR-1722; SER-1907; SER-2362; SER-2365; SER-2595; SER-3127;
RP   SER-3662; SER-3757; SER-3760 AND SER-3919, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1084; SER-1907; SER-2362
RP   AND SER-2365, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [32]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1368; SER-1382;
RP   SER-1395; THR-1722; SER-1907; SER-2266; SER-2362; SER-2365; SER-2527;
RP   SER-2532; SER-2535; THR-2554; SER-2595; SER-2887; SER-2888; THR-2889;
RP   SER-3116; SER-3117; SER-3122; SER-3127; SER-3135; SER-3555; SER-3662;
RP   SER-3752; SER-3757; SER-3760; SER-3808; SER-3816; SER-3827 AND
RP   THR-3830, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-740; SER-1368; SER-1395;
RP   THR-2035; SER-2584; SER-2826; SER-2833; SER-2835; SER-2861; SER-3757;
RP   SER-3759; SER-3816; SER-3827; SER-3906; SER-3919; THR-3924 AND
RP   THR-3927, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [34]
RP   STRUCTURE BY NMR OF 1317-1356.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of RSGI RUH-074, a human UBA domain.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [35]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 4005-4374.
RG   Structural genomics consortium (SGC);
RT   "Hect domain of human huwe1/mule.";
RL   Submitted (MAY-2009) to the PDB data bank.
RN   [36]
RP   VARIANTS MRXST HIS-2981; TRP-4013 AND CYS-4187, INVOLVEMENT IN MRX17,
RP   AND INVOLVEMENT IN MRXST.
RX   PubMed=18252223; DOI=10.1016/j.ajhg.2007.11.002;
RA   Froyen G., Corbett M., Vandewalle J., Jarvela I., Lawrence O.,
RA   Meldrum C., Bauters M., Govaerts K., Vandeleur L., Van Esch H.,
RA   Chelly J., Sanlaville D., van Bokhoven H., Ropers H.-H.,
RA   Laumonnier F., Ranieri E., Schwartz C.E., Abidi F., Tarpey P.S.,
RA   Futreal P.A., Whibley A., Raymond F.L., Stratton M.R., Fryns J.-P.,
RA   Scott R., Peippo M., Sipponen M., Partington M., Mowat D., Field M.,
RA   Hackett A., Marynen P., Turner G., Gecz J.;
RT   "Submicroscopic duplications of the hydroxysteroid dehydrogenase
RT   HSD17B10 and the E3 ubiquitin ligase HUWE1 are associated with mental
RT   retardation.";
RL   Am. J. Hum. Genet. 82:432-443(2008).
RN   [37]
RP   VARIANT ASP-950.
RX   PubMed=23092983; DOI=10.1038/tp.2012.102;
RA   Nava C., Lamari F., Heron D., Mignot C., Rastetter A., Keren B.,
RA   Cohen D., Faudet A., Bouteiller D., Gilleron M., Jacquette A.,
RA   Whalen S., Afenjar A., Perisse D., Laurent C., Dupuits C., Gautier C.,
RA   Gerard M., Huguet G., Caillet S., Leheup B., Leboyer M., Gillberg C.,
RA   Delorme R., Bourgeron T., Brice A., Depienne C.;
RT   "Analysis of the chromosome X exome in patients with autism spectrum
RT   disorders identified novel candidate genes, including TMLHE.";
RL   Transl. Psychiatry 2:E179-E179(2012).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase which mediates
CC       ubiquitination and subsequent proteasomal degradation of target
CC       proteins. Regulates apoptosis by catalyzing the polyubiquitination
CC       and degradation of MCL1. Mediates monoubiquitination of DNA
CC       polymerase beta (POLB) at 'Lys-41', 'Lys-61' and 'Lys-81', thereby
CC       playing a role in base-excision repair. Also ubiquitinates the
CC       p53/TP53 tumor suppressor and core histones including H1, H2A,
CC       H2B, H3 and H4. Binds to an upstream initiator-like sequence in
CC       the preprodynorphin gene. Regulates neural differentiation and
CC       proliferation by catalyzing the polyubiquitination and degradation
CC       of MYCN. May regulate abundance of CDC6 after DNA damage by
CC       polyubiquitinating and targeting CDC6 to degradation. Mediates
CC       polyubiquitination of isoform 2 of PA2G4.
CC       {ECO:0000269|PubMed:15567145, ECO:0000269|PubMed:15767685,
CC       ECO:0000269|PubMed:15989956, ECO:0000269|PubMed:15989957,
CC       ECO:0000269|PubMed:17567951, ECO:0000269|PubMed:18488021,
CC       ECO:0000269|PubMed:19037095, ECO:0000269|PubMed:19713937}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with isoform p14ARF of CDKN2A which strongly
CC       inhibits HUWE1 ubiquitin ligase activity. Interacts with MYCN,
CC       POLB and CDC6. Interacts with isoform 2 of PA2G4.
CC       {ECO:0000269|PubMed:15989956, ECO:0000269|PubMed:17567951,
CC       ECO:0000269|PubMed:18488021, ECO:0000269|PubMed:19037095,
CC       ECO:0000269|PubMed:19713937}.
CC   -!- INTERACTION:
CC       Q8N726:CDKN2A; NbExp=5; IntAct=EBI-625934, EBI-625922;
CC       P04792:HSPB1; NbExp=3; IntAct=EBI-625934, EBI-352682;
CC       P04637:TP53; NbExp=3; IntAct=EBI-625934, EBI-366083;
CC       Q13107:USP4; NbExp=4; IntAct=EBI-625934, EBI-723290;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:19713937}.
CC       Nucleus {ECO:0000269|PubMed:19713937}. Note=Mainly expressed in
CC       the cytoplasm of most tissues, except in the nucleus of
CC       spermatogonia, primary spermatocytes and neuronal cells (By
CC       similarity). Predominantly cytosolic or perinuclear in some
CC       colorectal carcinoma cells. {ECO:0000250|UniProtKB:Q7TMY8}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=LASU1, Large structure of UREB1;
CC         IsoId=Q7Z6Z7-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q7Z6Z7-2; Sequence=VSP_011146;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=Q7Z6Z7-3; Sequence=VSP_015272;
CC   -!- TISSUE SPECIFICITY: Weakly expressed in heart, brain and placenta
CC       but not in other tissues. Expressed in a number of cell lines,
CC       predominantly in those from colorectal carcinomas.
CC       {ECO:0000269|PubMed:15567145}.
CC   -!- DOMAIN: The HECT domain mediates inhibition of the transcriptional
CC       activity of p53.
CC   -!- PTM: Phosphorylated on tyrosine; phosphorylation is probably
CC       required for its ability to inhibit TP53 transactivation.
CC       {ECO:0000250|UniProtKB:Q7TMY8}.
CC   -!- DISEASE: Mental retardation, X-linked, syndromic, Turner type
CC       (MRXST) [MIM:300706]: A syndrome characterized by the association
CC       of mental retardation with macrocephaly and variable contractures.
CC       {ECO:0000269|PubMed:18252223}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Mental retardation, X-linked 17 (MRX17) [MIM:300705]: A
CC       disorder characterized by significantly below average general
CC       intellectual functioning associated with impairments in adaptive
CC       behavior and manifested during the developmental period.
CC       Intellectual deficiency is the only primary symptom of non-
CC       syndromic X-linked mental retardation, while syndromic mental
CC       retardation presents with associated physical, neurological and/or
CC       psychiatric manifestations. {ECO:0000269|PubMed:18252223}.
CC       Note=The gene represented in this entry is involved in disease
CC       pathogenesis. A chromosomal microduplication involving HSD17B10
CC       and HUWE1 has been found in patients with mental retardation.
CC   -!- SIMILARITY: Belongs to the UPL family. TOM1/PTR1 subfamily.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC62492.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAF28950.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC       Sequence=AAF28950.1; Type=Frameshift; Positions=4356; Evidence={ECO:0000305};
CC       Sequence=BAB13404.1; Type=Miscellaneous discrepancy; Note=Chimeric cDNA, contains the C-terminal part of ATP5I.; Evidence={ECO:0000305};
CC       Sequence=BAC06833.1; Type=Frameshift; Positions=982, 1055; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AY772009; AAV90838.1; -; mRNA.
DR   EMBL; DQ097177; AAY98258.1; -; mRNA.
DR   EMBL; AY929612; AAX24125.1; -; mRNA.
DR   EMBL; AL592046; CAI39580.1; -; Genomic_DNA.
DR   EMBL; Z94044; CAI39580.1; JOINED; Genomic_DNA.
DR   EMBL; Z97054; CAI39580.1; JOINED; Genomic_DNA.
DR   EMBL; Z94044; CAI42354.1; -; Genomic_DNA.
DR   EMBL; AL592046; CAI42354.1; JOINED; Genomic_DNA.
DR   EMBL; Z97054; CAI42354.1; JOINED; Genomic_DNA.
DR   EMBL; Z97054; CAI42654.1; -; Genomic_DNA.
DR   EMBL; AL592046; CAI42654.1; JOINED; Genomic_DNA.
DR   EMBL; Z94044; CAI42654.1; JOINED; Genomic_DNA.
DR   EMBL; AB071605; BAC06833.1; ALT_FRAME; mRNA.
DR   EMBL; AB002310; BAA20771.3; -; mRNA.
DR   EMBL; AB046798; BAB13404.1; ALT_SEQ; mRNA.
DR   EMBL; AF161390; AAF28950.1; ALT_SEQ; mRNA.
DR   EMBL; BC002602; AAH02602.2; -; mRNA.
DR   EMBL; BC063505; AAH63505.1; -; mRNA.
DR   EMBL; AF057569; AAC62492.1; ALT_INIT; mRNA.
DR   EMBL; CR456813; CAG33094.1; -; mRNA.
DR   EMBL; AL162050; CAB82393.1; -; mRNA.
DR   CCDS; CCDS35301.1; -. [Q7Z6Z7-1]
DR   PIR; T47165; T47165.
DR   RefSeq; NP_113584.3; NM_031407.6. [Q7Z6Z7-1]
DR   RefSeq; XP_005262022.1; XM_005261965.3. [Q7Z6Z7-1]
DR   UniGene; Hs.136905; -.
DR   PDB; 2EKK; NMR; -; A=1317-1356.
DR   PDB; 2MUL; NMR; -; A=2951-3003.
DR   PDB; 3G1N; X-ray; 2.60 A; A/B=4005-4374.
DR   PDB; 3H1D; X-ray; 1.89 A; A=3993-4374.
DR   PDB; 5C6H; X-ray; 2.05 A; B/D/F/H/J/L/N/P/R/T/V/X=1969-1994.
DR   PDB; 5LP8; X-ray; 2.70 A; A/B=3951-4374.
DR   PDBsum; 2EKK; -.
DR   PDBsum; 2MUL; -.
DR   PDBsum; 3G1N; -.
DR   PDBsum; 3H1D; -.
DR   PDBsum; 5C6H; -.
DR   PDBsum; 5LP8; -.
DR   ProteinModelPortal; Q7Z6Z7; -.
DR   SMR; Q7Z6Z7; -.
DR   BioGrid; 115385; 462.
DR   DIP; DIP-34362N; -.
DR   IntAct; Q7Z6Z7; 79.
DR   MINT; MINT-1576525; -.
DR   STRING; 9606.ENSP00000262854; -.
DR   iPTMnet; Q7Z6Z7; -.
DR   PhosphoSitePlus; Q7Z6Z7; -.
DR   BioMuta; HUWE1; -.
DR   DMDM; 73915353; -.
DR   EPD; Q7Z6Z7; -.
DR   MaxQB; Q7Z6Z7; -.
DR   PaxDb; Q7Z6Z7; -.
DR   PeptideAtlas; Q7Z6Z7; -.
DR   PRIDE; Q7Z6Z7; -.
DR   Ensembl; ENST00000262854; ENSP00000262854; ENSG00000086758. [Q7Z6Z7-1]
DR   Ensembl; ENST00000342160; ENSP00000340648; ENSG00000086758. [Q7Z6Z7-1]
DR   Ensembl; ENST00000612484; ENSP00000479451; ENSG00000086758. [Q7Z6Z7-3]
DR   GeneID; 10075; -.
DR   KEGG; hsa:10075; -.
DR   UCSC; uc033eew.2; human. [Q7Z6Z7-1]
DR   CTD; 10075; -.
DR   DisGeNET; 10075; -.
DR   GeneCards; HUWE1; -.
DR   HGNC; HGNC:30892; HUWE1.
DR   HPA; CAB022718; -.
DR   HPA; HPA002548; -.
DR   MalaCards; HUWE1; -.
DR   MIM; 300697; gene.
DR   MIM; 300705; phenotype.
DR   MIM; 300706; phenotype.
DR   neXtProt; NX_Q7Z6Z7; -.
DR   OpenTargets; ENSG00000086758; -.
DR   Orphanet; 85328; X-linked intellectual disability, Turner type.
DR   PharmGKB; PA128394567; -.
DR   eggNOG; KOG0939; Eukaryota.
DR   eggNOG; COG5021; LUCA.
DR   GeneTree; ENSGT00850000132302; -.
DR   HOVERGEN; HBG080254; -.
DR   InParanoid; Q7Z6Z7; -.
DR   KO; K10592; -.
DR   OMA; HAFEFIF; -.
DR   OrthoDB; EOG091G01V1; -.
DR   PhylomeDB; Q7Z6Z7; -.
DR   TreeFam; TF323417; -.
DR   BRENDA; 6.3.2.19; 2681.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   Reactome; R-HSA-983168; Antigen processing: Ubiquitination & Proteasome degradation.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; HUWE1; human.
DR   EvolutionaryTrace; Q7Z6Z7; -.
DR   GeneWiki; HUWE1; -.
DR   GenomeRNAi; 10075; -.
DR   PRO; PR:Q7Z6Z7; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   Bgee; ENSG00000086758; -.
DR   ExpressionAtlas; Q7Z6Z7; baseline and differential.
DR   Genevisible; Q7Z6Z7; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:1904813; C:ficolin-1-rich granule lumen; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0034774; C:secretory granule lumen; TAS:Reactome.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0006284; P:base-excision repair; IMP:UniProtKB.
DR   GO; GO:0030154; P:cell differentiation; IEA:UniProtKB-KW.
DR   GO; GO:0016574; P:histone ubiquitination; IDA:UniProtKB.
DR   GO; GO:0043312; P:neutrophil degranulation; TAS:Reactome.
DR   GO; GO:1903955; P:positive regulation of protein targeting to mitochondrion; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0006513; P:protein monoubiquitination; IDA:UniProtKB.
DR   GO; GO:0000209; P:protein polyubiquitination; IDA:UniProtKB.
DR   CDD; cd00078; HECTc; 1.
DR   Gene3D; 1.25.10.10; -; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR025527; DUF4414.
DR   InterPro; IPR010309; E3_Ub_ligase_DUF908.
DR   InterPro; IPR010314; E3_Ub_ligase_DUF913.
DR   InterPro; IPR000569; HECT_dom.
DR   InterPro; IPR015940; UBA.
DR   InterPro; IPR009060; UBA-like.
DR   InterPro; IPR004170; WWE-dom.
DR   Pfam; PF14377; DUF4414; 1.
DR   Pfam; PF06012; DUF908; 1.
DR   Pfam; PF06025; DUF913; 1.
DR   Pfam; PF00632; HECT; 1.
DR   Pfam; PF00627; UBA; 1.
DR   Pfam; PF02825; WWE; 1.
DR   SMART; SM00119; HECTc; 1.
DR   SMART; SM00165; UBA; 1.
DR   SUPFAM; SSF46934; SSF46934; 1.
DR   SUPFAM; SSF48371; SSF48371; 3.
DR   SUPFAM; SSF56204; SSF56204; 1.
DR   PROSITE; PS50237; HECT; 1.
DR   PROSITE; PS50030; UBA; 1.
DR   PROSITE; PS50918; WWE; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing;
KW   Chromosomal rearrangement; Complete proteome; Cytoplasm;
KW   Differentiation; Disease mutation; DNA damage; DNA repair;
KW   DNA-binding; Mental retardation; Methylation; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Transferase;
KW   Ubl conjugation pathway.
FT   CHAIN         1   4374       E3 ubiquitin-protein ligase HUWE1.
FT                                /FTId=PRO_0000120340.
FT   DOMAIN     1316   1355       UBA. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00212}.
FT   DOMAIN     1370   1389       UIM. {ECO:0000305}.
FT   DOMAIN     1603   1680       WWE. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00248}.
FT   DOMAIN     4038   4374       HECT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00104}.
FT   COMPBIAS   2295   2469       Glu-rich.
FT   COMPBIAS   2427   2490       Asp-rich.
FT   COMPBIAS   3483   3550       Thr-rich.
FT   ACT_SITE   4341   4341       Glycyl thioester intermediate.
FT   MOD_RES     648    648       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q7TMY8}.
FT   MOD_RES     649    649       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q7TMY8}.
FT   MOD_RES     740    740       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1084   1084       Phosphoserine.
FT                                {ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES    1368   1368       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1370   1370       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES    1382   1382       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1395   1395       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    1722   1722       Phosphothreonine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    1907   1907       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2035   2035       Phosphothreonine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    2266   2266       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2267   2267       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q7TMY8}.
FT   MOD_RES    2362   2362       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2365   2365       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2391   2391       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES    2527   2527       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2532   2532       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2535   2535       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2554   2554       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2584   2584       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    2595   2595       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2619   2619       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES    2751   2751       Phosphothreonine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES    2826   2826       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    2833   2833       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    2835   2835       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    2861   2861       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    2887   2887       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2888   2888       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2889   2889       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2918   2918       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243}.
FT   MOD_RES    3116   3116       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3117   3117       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3122   3122       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3127   3127       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3135   3135       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3149   3149       Omega-N-methylarginine.
FT                                {ECO:0000250|UniProtKB:Q7TMY8}.
FT   MOD_RES    3555   3555       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3662   3662       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3752   3752       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3757   3757       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    3759   3759       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    3760   3760       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3808   3808       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3816   3816       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    3827   3827       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    3830   3830       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES    3906   3906       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES    3919   3919       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    3924   3924       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES    3927   3927       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ     982    990       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.5}.
FT                                /FTId=VSP_015272.
FT   VAR_SEQ    3016   3031       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:9205841}.
FT                                /FTId=VSP_011146.
FT   VARIANT     483    483       N -> S (in dbSNP:rs41307640).
FT                                /FTId=VAR_061986.
FT   VARIANT     950    950       V -> D (found in patients with autism
FT                                spectrum disorders; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23092983}.
FT                                /FTId=VAR_076253.
FT   VARIANT    2981   2981       R -> H (in MRXST; dbSNP:rs121918526).
FT                                {ECO:0000269|PubMed:18252223}.
FT                                /FTId=VAR_045670.
FT   VARIANT    4013   4013       R -> W (in MRXST; dbSNP:rs121918525).
FT                                {ECO:0000269|PubMed:18252223}.
FT                                /FTId=VAR_045671.
FT   VARIANT    4187   4187       R -> C (in MRXST; dbSNP:rs121918527).
FT                                {ECO:0000269|PubMed:18252223}.
FT                                /FTId=VAR_045672.
FT   MUTAGEN    4268   4268       Y->S: Loss of activity.
FT                                {ECO:0000269|PubMed:15567145}.
FT   MUTAGEN    4341   4341       C->A,D: Loss of activity.
FT                                {ECO:0000269|PubMed:15567145,
FT                                ECO:0000269|PubMed:15989956,
FT                                ECO:0000269|PubMed:15989957,
FT                                ECO:0000269|PubMed:18488021}.
FT   CONFLICT   1111   1111       K -> N (in Ref. 5; BAC06833).
FT                                {ECO:0000305}.
FT   CONFLICT   1124   1124       P -> L (in Ref. 1; AAV90838 and 5;
FT                                BAC06833). {ECO:0000305}.
FT   CONFLICT   1190   1190       D -> H (in Ref. 5; BAC06833).
FT                                {ECO:0000305}.
FT   CONFLICT   1962   1962       Missing (in Ref. 6; BAA20771).
FT                                {ECO:0000305}.
FT   CONFLICT   2525   2525       H -> Y (in Ref. 5; BAC06833 and 9;
FT                                AAF28950). {ECO:0000305}.
FT   CONFLICT   4022   4022       R -> L (in Ref. 10; AAH02602).
FT                                {ECO:0000305}.
FT   HELIX      1319   1329       {ECO:0000244|PDB:2EKK}.
FT   HELIX      1332   1341       {ECO:0000244|PDB:2EKK}.
FT   HELIX      1345   1353       {ECO:0000244|PDB:2EKK}.
FT   HELIX      1976   1991       {ECO:0000244|PDB:5C6H}.
FT   HELIX      2958   2960       {ECO:0000244|PDB:2MUL}.
FT   HELIX      2970   2975       {ECO:0000244|PDB:2MUL}.
FT   HELIX      2978   2988       {ECO:0000244|PDB:2MUL}.
FT   HELIX      3952   3972       {ECO:0000244|PDB:5LP8}.
FT   TURN       3977   3979       {ECO:0000244|PDB:5LP8}.
FT   HELIX      3983   3991       {ECO:0000244|PDB:5LP8}.
FT   HELIX      3994   4008       {ECO:0000244|PDB:3H1D}.
FT   TURN       4009   4011       {ECO:0000244|PDB:3H1D}.
FT   STRAND     4016   4021       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4023   4025       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4026   4034       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4041   4043       {ECO:0000244|PDB:3H1D}.
FT   STRAND     4044   4050       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4061   4072       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4076   4078       {ECO:0000244|PDB:3H1D}.
FT   STRAND     4080   4083       {ECO:0000244|PDB:3H1D}.
FT   TURN       4085   4087       {ECO:0000244|PDB:3G1N}.
FT   STRAND     4088   4093       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4095   4099       {ECO:0000244|PDB:3G1N}.
FT   HELIX      4103   4120       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4130   4137       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4143   4145       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4146   4149       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4151   4162       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4165   4167       {ECO:0000244|PDB:3H1D}.
FT   STRAND     4168   4170       {ECO:0000244|PDB:3H1D}.
FT   STRAND     4172   4175       {ECO:0000244|PDB:3H1D}.
FT   TURN       4176   4178       {ECO:0000244|PDB:3H1D}.
FT   STRAND     4181   4183       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4186   4189       {ECO:0000244|PDB:3H1D}.
FT   STRAND     4193   4197       {ECO:0000244|PDB:3H1D}.
FT   TURN       4200   4202       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4203   4215       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4217   4219       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4220   4233       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4236   4239       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4244   4252       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4259   4264       {ECO:0000244|PDB:3H1D}.
FT   STRAND     4266   4271       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4276   4287       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4290   4301       {ECO:0000244|PDB:3H1D}.
FT   STRAND     4302   4304       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4311   4313       {ECO:0000244|PDB:3H1D}.
FT   STRAND     4317   4320       {ECO:0000244|PDB:3H1D}.
FT   STRAND     4323   4328       {ECO:0000244|PDB:3H1D}.
FT   STRAND     4337   4339       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4340   4342       {ECO:0000244|PDB:3H1D}.
FT   STRAND     4344   4348       {ECO:0000244|PDB:3H1D}.
FT   HELIX      4353   4365       {ECO:0000244|PDB:3H1D}.
FT   STRAND     4370   4372       {ECO:0000244|PDB:5LP8}.
SQ   SEQUENCE   4374 AA;  481891 MW;  FA9D3A7712F6393B CRC64;
     MKVDRTKLKK TPTEAPADCR ALIDKLKVCN DEQLLLELQQ IKTWNIGKCE LYHWVDLLDR
     FDGILADAGQ TVENMSWMLV CDRPEREQLK MLLLAVLNFT ALLIEYSFSR HLYSSIEHLT
     TLLASSDMQV VLAVLNLLYV FSKRSNYITR LGSDKRTPLL TRLQHLAESW GGKENGFGLA
     ECCRDLHMMK YPPSATTLHF EFYADPGAEV KIEKRTTSNT LHYIHIEQLD KISESPSEIM
     ESLTKMYSIP KDKQMLLFTH IRLAHGFSNH RKRLQAVQAR LHAISILVYS NALQESANSI
     LYNGLIEELV DVLQITDKQL MEIKAASLRT LTSIVHLERT PKLSSIIDCT GTASYHGFLP
     VLVRNCIQAM IDPSMDPYPH QFATALFSFL YHLASYDAGG EALVSCGMME ALLKVIKFLG
     DEQDQITFVT RAVRVVDLIT NLDMAAFQSH SGLSIFIYRL EHEVDLCRKE CPFVIKPKIQ
     RPNTTQEGEE METDMDGVQC IPQRAALLKS MLNFLKKAIQ DPAFSDGIRH VMDGSLPTSL
     KHIISNAEYY GPSLFLLATE VVTVFVFQEP SLLSSLQDNG LTDVMLHALL IKDVPATREV
     LGSLPNVFSA LCLNARGLQS FVQCQPFERL FKVLLSPDYL PAMRRRRSSD PLGDTASNLG
     SAVDELMRHQ PTLKTDATTA IIKLLEEICN LGRDPKYICQ KPSIQKADGT ATAPPPRSNH
     AAEEASSEDE EEEEVQAMQS FNSTQQNETE PNQQVVGTEE RIPIPLMDYI LNVMKFVESI
     LSNNTTDDHC QEFVNQKGLL PLVTILGLPN LPIDFPTSAA CQAVAGVCKS ILTLSHEPKV
     LQEGLLQLDS ILSSLEPLHR PIESPGGSVL LRELACAGNV ADATLSAQAT PLLHALTAAH
     AYIMMFVHTC RVGQSEIRSI SVNQWGSQLG LSVLSKLSQL YCSLVWESTV LLSLCTPNSL
     PSGCEFGQAD MQKLVPKDEK AGTTQGGKRS DGEQDGAAGS MDASTQGLLE GIGLDGDTLA
     PMETDEPTAS DSKGKSKITP AMAARIKQIK PLLSASSRLG RALAELFGLL VKLCVGSPVR
     QRRSHHAAST TTAPTPAARS TASALTKLLT KGLSWQPPPY TPTPRFRLTF FICSVGFTSP
     MLFDERKYPY HLMLQKFLCS GGHNALFETF NWALSMGGKV PVSEGLEHSD LPDGTGEFLD
     AWLMLVEKMV NPTTVLESPH SLPAKLPGGV QNFPQFSALR FLVVTQKAAF TCIKNLWNRK
     PLKVYGGRMA ESMLAILCHI LRGEPVIRER LSKEKEGSRG EEDTGQEEGG SRREPQVNQQ
     QLQQLMDMGF TREHAMEALL NTSTMEQATE YLLTHPPPIM GGVVRDLSMS EEDQMMRAIA
     MSLGQDIPMD QRAESPEEVA CRKEEEERKA REKQEEEEAK CLEKFQDADP LEQDELHTFT
     DTMLPGCFHL LDELPDTVYR VCDLIMTAIK RNGADYRDMI LKQVVNQVWE AADVLIKAAL
     PLTTSDTKTV SEWISQMATL PQASNLATRI LLLTLLFEEL KLPCAWVVES SGILNVLIKL
     LEVVQPCLQA AKEQKEVQTP KWITPVLLLI DFYEKTAISS KRRAQMTKYL QSNSNNWRWF
     DDRSGRWCSY SASNNSTIDS AWKSGETSVR FTAGRRRYTV QFTTMVQVNE ETGNRRPVML
     TLLRVPRLNK NSKNSNGQEL EKTLEESKEM DIKRKENKGN DTPLALESTN TEKETSLEET
     KIGEILIQGL TEDMVTVLIR ACVSMLGVPV DPDTLHATLR LCLRLTRDHK YAMMFAELKS
     TRMILNLTQS SGFNGFTPLV TLLLRHIIED PCTLRHTMEK VVRSAATSGA GSTTSGVVSG
     SLGSREINYI LRVLGPAACR NPDIFTEVAN CCIRIALPAP RGSGTASDDE FENLRIKGPN
     AVQLVKTTPL KPSPLPVIPD TIKEVIYDML NALAAYHAPE EADKSDPKPG VMTQEVGQLL
     QDMGDDVYQQ YRSLTRQSSD FDTQSGFSIN SQVFAADGAS TETSASGTSQ GEASTPEESR
     DGKKDKEGDR ASEEGKQKGK GSKPLMPTST ILRLLAELVR SYVGIATLIA NYSYTVGQSE
     LIKEDCSVLA FVLDHLLPHT QNAEDKDTPA LARLFLASLA AAGSGTDAQV ALVNEVKAAL
     GRALAMAEST EKHARLQAVM CIISTIMESC PSTSSFYSSA TAKTQHNGMN NIIRLFLKKG
     LVNDLARVPH SLDLSSPNMA NTVNAALKPL ETLSRIVNQP SSLFGSKSAS SKNKSEQDAQ
     GASQDSSSNQ QDPGEPGEAE VQEEDHDVTQ TEVADGDIMD GEAETDSVVI AGQPEVLSSQ
     EMQVENELED LIDELLERDG GSGNSTIIVS RSGEDESQED VLMDEAPSNL SQASTLQANR
     EDSMNILDPE DEEEHTQEED SSGSNEDEDD SQDEEEEEEE DEEDDQEDDE GEEGDEDDDD
     DGSEMELDED YPDMNASPLV RFERFDREDD LIIEFDNMFS SATDIPPSPG NIPTTHPLMV
     RHADHSSLTL GSGSSTTRLT QGIGRSQRTL RQLTANTGHT IHVHYPGNRQ PNPPLILQRL
     LGPSAAADIL QLSSSLPLQS RGRARLLVGN DDVHIIARSD DELLDDFFHD QSTATSQAGT
     LSSIPTALTR WTEECKVLDA ESMHDCVSVV KVSIVNHLEF LRDEELEERR EKRRKQLAEE
     ETKITDKGKE DKENRDQSAQ CTASKSNDST EQNLSDGTPM PDSYPTTPSS TDAATSESKE
     TLGTLQSSQQ QPTLPTPPAL GEVPQELQSP AGEGGSSTQL LMPVEPEELG PTRPSGEAET
     TQMELSPAPT ITSLSPERAE DSDALTAVSS QLEGSPMDTS SLASCTLEEA VGDTSAAGSS
     EQPRAGSSTP GDAPPAVAEV QGRSDGSGES AQPPEDSSPP ASSESSSTRD SAVAISGADS
     RGILEEPLPS TSSEEEDPLA GISLPEGVDP SFLAALPDDI RREVLQNQLG IRPPTRTAPS
     TNSSAPAVVG NPGVTEVSPE FLAALPPAIQ EEVLAQQRAE QQRRELAQNA SSDTPMDPVT
     FIQTLPSDLR RSVLEDMEDS VLAVMPPDIA AEAQALRREQ EARQRQLMHE RLFGHSSTSA
     LSAILRSPAF TSRLSGNRGV QYTRLAVQRG GTFQMGGSSS HNRPSGSNVD TLLRLRGRLL
     LDHEALSCLL VLLFVDEPKL NTSRLHRVLR NLCYHAQTRH WVIRSLLSIL QRSSESELCI
     ETPKLTTSEE KGKKSSKSCG SSSHENRPLD LLHKMESKSS NQLSWLSVSM DAALGCRTNI
     FQIQRSGGRK HTEKHASGGS TVHIHPQAAP VVCRHVLDTL IQLAKVFPSH FTQQRTKETN
     CESDRERGNK ACSPCSSQSS SSGICTDFWD LLVKLDNMNV SRKGKNSVKS VPVSAGGEGE
     TSPYSLEASP LGQLMNMLSH PVIRRSSLLT EKLLRLLSLI SIALPENKVS EAQANSGSGA
     SSTTTATSTT STTTTTAAST TPTPPTAPTP VTSAPALVAA TAISTIVVAA STTVTTPTTA
     TTTVSISPTT KGSKSPAKVS DGGSSSTDFK MVSSGLTENQ LQLSVEVLTS HSCSEEGLED
     AANVLLQLSR GDSGTRDTVL KLLLNGARHL GYTLCKQIGT LLAELREYNL EQQRRAQCET
     LSPDGLPEEQ PQTTKLKGKM QSRFDMAENV VIVASQKRPL GGRELQLPSM SMLTSKTSTQ
     KFFLRVLQVI IQLRDDTRRA NKKAKQTGRL GSSGLGSASS IQAAVRQLEA EADAIIQMVR
     EGQRARRQQQ AATSESSQSE ASVRREESPM DVDQPSPSAQ DTQSIASDGT PQGEKEKEER
     PPELPLLSEQ LSLDELWDML GECLKELEES HDQHAVLVLQ PAVEAFFLVH ATERESKPPV
     RDTRESQLAH IKDEPPPLSP APLTPATPSS LDPFFSREPS SMHISSSLPP DTQKFLRFAE
     THRTVLNQIL RQSTTHLADG PFAVLVDYIR VLDFDVKRKY FRQELERLDE GLRKEDMAVH
     VRRDHVFEDS YRELHRKSPE EMKNRLYIVF EGEEGQDAGG LLREWYMIIS REMFNPMYAL
     FRTSPGDRVT YTINPSSHCN PNHLSYFKFV GRIVAKAVYD NRLLECYFTR SFYKHILGKS
     VRYTDMESED YHFYQGLVYL LENDVSTLGY DLTFSTEVQE FGVCEVRDLK PNGANILVTE
     ENKKEYVHLV CQMRMTGAIR KQLAAFLEGF YEIIPKRLIS IFTEQELELL ISGLPTIDID
     DLKSNTEYHK YQSNSIQIQW FWRALRSFDQ ADRAKFLQFV TGTSKVPLQG FAALEGMNGI
     QKFQIHRDDR STDRLPSAHT CFNQLDLPAY ESFEKLRHML LLAIQECSEG FGLA
//
